You are here

  • Home
  • Archive
  • Volume 10, Issue 4
  • Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT

Article metrics

Article menu
Immune cell therapies and immune cell engineering
Original research
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT

 

Online download statistics by month:

Online download statistics by month: April 2022 to August 2025

AbstractFullPdf
Apr 2022468475131
May 2022280289150
Jun 202214715360
Jul 202212012571
Aug 202212112637
Sep 202211612247
Oct 202211311644
Nov 2022989835
Dec 2022919117
Jan 2023595913
Feb 2023747429
Mar 2023404135
Apr 2023343416
May 2023363614
Jun 2023313112
Jul 2023454529
Aug 2023303019
Sep 2023282815
Oct 2023272718
Nov 2023383814
Dec 2023686820
Jan 2024424337
Feb 2024383829
Mar 2024293078
Apr 2024464727
May 2024424335
Jun 2024424128
Jul 2024808127
Aug 2024545522
Sep 2024404091
Oct 2024393921
Nov 2024464725
Dec 2024414319
Jan 2025394233
Feb 202512312331
Mar 2025464645
Apr 2025444427
May 2025393926
Jun 2025363617
Jul 2025110
Aug 2025110
Total293229851444